Compare Hims and Hers Health Inc (HIMS) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs HubSpot Inc — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while HubSpot Inc trades at $228.3 (market cap $11.56B). The key difference: HubSpot Inc is the larger of the two by market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and HubSpot Inc for 78 Days on average.
| HIMS | HUBS | |
|---|---|---|
Market Cap | $6.55B | $11.56B |
Volume | 14,842,814 | 1,891,287 |
Sector | Health | Technology |
52-Week High | $62.76 | $494.58 |
52-Week Low | $14.52 | $170.39 |
Typical Hold Time | 21 Days | 78 Days |
Enterprise Value | $7.25B | $10.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
HubSpot (HUBS) trades at $228.30, up 3.63% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with improving profitability, though valuation ratios remain elevated. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though risks include high P/E ratio, competitive pressures, and potential AI disruption concerns. The stock offers growth exposure with solid cash flow generation but requires monitoring of execution against ambitious margin targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
